HIV Treatment: Venetoclax Study

We are testing the safety of a medication called venetoclax in people living with HIV who are on antiretroviral therapy. The aim is to see if it can help reduce the size of the HIV reservoir in the body.

1-2 years11-15 visitsSafety phase (I)Efficacy phase (II)No PlaceboPartially RemoteStandard MedicinesOralHematologyInfectious Diseases

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Venclyxto
Venclyxto is a medicine used to treat certain types of blood cancer, including some forms of leukemia and lymphoma.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Venetoclax
Venetoclax is a substance used to treat certain blood cancers by helping cancer cells die.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Aarhus University Hospital
Infectious Diseases
Århus, Denmark
Sponsor: Aarhus University Hospital
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.